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Abstract
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Terminal erythroid differentiation occurs in the bone marrow, within specialized niches termed
erythroblastic islands. These functional units consist of a macrophage surrounded by
differentiating erythroblasts and have been described more than five decades ago but their function
in the pathophysiology of erythropoiesis has remained unclear until recently. Here we propose that
the central macrophage in the erythroblastic island contributes to the pathophysiology of anemia
of inflammation. After introducing erythropoiesis and the interactions between the erythroblasts
and the central macrophage within the erythroblastic islands, we will discuss the
immunophenotypic characterization of this specific subpopulation of macrophages. We will then
integrate these concepts into the currently known pathophysiological drivers of anemia of
inflammation and address the role of the central macrophage in this disorder. Finally, as a means
of furthering our understanding of the various concepts, we will discuss the differences between
murine and rat models with regards to developmental and stress erythropoiesis in an attempt to
define a model system representative of human pathophysiology.
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Anemia, defined by a decrease in the hemoglobin concentration, results from either
increased peripheral destruction or decreased production of red blood cells (RBCs) or both.
Anemia of inflammation is the second most common cause of anemia after iron deficiency
[1] and is primarily an immune driven pathologic process that is frequently associated with
various conditions, such as acute and chronic infections, sepsis, malignancies, autoimmune
disorders, and chronic kidney disease [2]. Anemia of inflammation presents a clinical
challenge as its consequences in the context of the aforementioned associated conditions
leads to poorer prognosis, particularly in elderly patients with preexisting risk factors such
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as coronary artery disease, pulmonary disease, and chronic kidney disease [3]. In the most
clinically dire cases such as in sepsis, the recommendation guidelines published by the
Surviving Sepsis campaign [4] includes the usage of transfusions to obtain a hematocrit of
30%, which was found to be correlated with better patient outcomes than those who did not
[5]. However, the limited clinical efficacy of repeated transfusions to correct anemia of
inflammation suggests the need for an improvement in therapeutic strategies. In this context,
increasing the red cell mass and thereby the hemoglobin concentration by stimulating red
cell production remains appealing. Due to the complex nature of anemia of inflammation, a
more complete understanding of erythropoiesis during both normal physiology and anemia
of inflammation are warranted.
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In the present review, we will first discuss erythropoiesis as a finely tuned cellular process.
We will then introduce the erythroblastic island, the specialized niche within the bone
marrow that support erythropoiesis; and expand on the known and putative roles played by
bone marrow-derived macrophages at the center of these anatomic niches. We will integrate
these concepts into the currently known pathophysiological drivers of anemia of
inflammation and address areas requiring further research. Finally, as a means to answer
these questions, we will discuss the differences between murine and rat models in regards to
developmental erythropoiesis in an attempt to define a model system representative of
human pathophysiology.

Erythropoiesis in the normal adult and its regulation by erythropoietin
From the hematopoietic stem cell to the red blood cell
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Erythropoiesis in humans is an essential and highly regulated process that maintains the
production of 2×1011 RBCs per day needed to maintain homeostatic oxygen delivery to
tissues. In the bone marrow, red cell formation begins with the proliferation and
commitment of the hematopoietic stem cell (HSC). Multipotent and minimally selfrenewing short-term hematopoietic stem cells (ST-HSC) acquire hematopoietic lineage
restricted transcription factors that drive differentiation to an erythroid/myeloid/
megakaryocytic-forming progenitor, the common myeloid progenitor (CMP). The CMP
expresses the transcription factors Tal1/SCL, GATA-2, NF-E2, GATA-1, C/EBPa, c-Myb,
and PU.1 [6]. Further erythroid restriction to the megakaryocyte-erythroid progenitor (MEP)
at the CMP stage requires the dominant expression of GATA-1, the master erythroid
transcription factor, at the expense of PU.1 [7]. As hematopoietic progenitors progressively
mature, they upregulate another erythroid-specific transcriptional factor, EKLF/KLF1,
beginning as early as the CMP stage [8]. KLF1 itself is necessary for both the cell fate
decisions at the MEP level and the transition from erythroid precursors (the Burst Forming
Unit-Erythroid, BFU-E, and Colony Forming Unit-Erythroid, CFU-E) to the terminally
differentiating erythroblasts. Indeed, overexpression of KLF1 induces greater levels of
erythropoiesis than megakaryopoiesis from the MEP population with high numbers of
developing erythroblasts [9]. Conversely, knockdown of KLF1 favors megakaryocyte
formation and prevents the transition of CFU-E to the proerythroblasts [10], highlighting the
central role of KLF-1 in lineage fate decisions.
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Terminal erythroblast maturation marks the final stages of erythropoiesis, and takes place in
a specialized erythroid microenvironment, the erythroblastic island, which will be discussed
in greater details in this review. Proerythroblasts proceed through a number of subsequent
mitoses to sequentially generate basophilic erythroblasts, polychromatic erythroblasts, and
orthochromatic erythroblasts. This process is regulated notably by the concerted function of
GATA-1, Tal1/SCL, LMO2, LDB1 and KLF1 [11]. Many of these regulatory proteins share
overlapping areas of chromatin to modify gene expression (e.g. GATA-1 and KLF1) [12].
During terminal maturation, hemoglobin synthesis increases, cell size decreases, and the
nucleus condenses. The condensed nucleus of the orthochromatic erythroblast is expelled
through the intricate process of enucleation [13,14], and the central macrophage engulfs and
degrades the newly released pyrenocyte, a pyknotic nucleus surrounded by a rim of
cytoplasm and plasma membrane [15,16]. Recognized as a necessary step for mammalian
erythropoiesis [17], the molecular mechanisms underlying enucleation are still not entirely
clear. Nascent reticulocytes remain in the bone marrow for about 48 hours, and then enter
the bloodstream where they mature for an additional 24 hours. Reticulocyte maturation
completes erythropoiesis, with the elimination of the remnants of internal organelles [18–20]
and extensive membrane remodeling [21,22]. Ultimately, mature erythrocytes survive for
about 120 days in the blood stream. Figure 1 summarizes the different stages of
erythropoiesis.
Regulation of erythropoiesis by erythropoietin
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Of the many intrinsic and extrinsic factors that regulate red cell mass, the hormone
erythropoietin (EPO) is the best studied and important in the context of anemia of
inflammation. Decreased erythrocyte numbers and subsequent hypoxia stimulates EPO
production by a heterogeneous population of peritubular interstitial fibroblast-like cells in
the kidneys [23,24]. Crucial to the induction of EPO synthesis in these hypoxia-sensing cells
is the regulation of intracellular hypoxia inducible factor-2α (HIF-2α) levels. Under
normoxic conditions, the concerted function of prolyl hydroxylase and Von Hippel-Lindau
target HIF-2α for degradation. However, hypoxia prevents hydroxylation of HIF-2α, and
results in the stabilization of HIF-2α [25]. HIF-2α then translocates to the nucleus where it
binds to regulatory elements upstream of the EPO gene to induce its expression and
secretion [26]. EPO levels in the plasma then rise and the hormone acts on the bone marrow
compartment where it stimulates red cell production. However, not all differentiating
erythroid cells are sensitive to EPO (Figure 1). Indeed, the EPO receptor (EPO-R) is only
expressed from the CFU-E to the basophilic erythroblast stages [27], as shown in Figure 1.
At the molecular level, the signaling cascade leading to prevention of apoptosis of
erythroblasts by Epo has been identified [28]. Once EPO binds to its receptor, its triggers
phosphorylation of EPO-R, and subsequently, the activation of the STAT5, PI3-kinase/Akt,
and MAP-ERK transduction pathways [29]. Ultimately, there is a decrease in the quantity of
Fas membrane protein in response to EPO signaling, leading to a decrease in apoptosis [30].
Thus, EPO is a critical factor for erythroblast survival.
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Erythroblastic Islands
Definition
The term erythroblastic island first appeared in the literature in 1958, when the French
hematologist, Marcel Bessis, proposed it as “the functional unit of the bone marrow” [31]. In
1978, Mohandas and Prenant produced a three-dimensional reconstruction of the rat bone
marrow, and confirmed Bessis’ original hypothesis [32]. These erythroblastic islands are
specific to fetal and adult erythropoiesis and are not observed in the yolk sac [33]. As many
as 30 to 48 developing erythroid cells, ranging from the CFU-E to the reticulocyte stage are
found to be associated with macrophages also known as the central macrophage [31,34].
Interactions between differentiating erythroblasts and the central macrophage
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Although erythroblasts can proliferate and enucleate in the absence of macrophages in vitro,
this process is still relatively inefficient in comparison to the rates of erythropoiesis in vivo
[35,36], highlighting the critical role for cell-cell interactions in physiological regulation of
red cell production. Indeed, macrophages and erythroblasts share many cell-cell adhesion
molecules. One of the first molecules identified in mediating the erythroblast-macrophage
adhesive interactions was EMP (erythroblast macrophage protein, also known as
macrophage erythroblast attacher, MAEA), which enables the interaction of developing
erythroblasts with the macrophages via homophilic interactions [37]. Blockade of EMP
using anti-EMP during in vitro studies resulted in decreased proliferation, maturation and
enucleation [35], and Emp−/− mice presented with severe anemia and perinatal death [38].
Several other sets of critical adhesion molecules have been subsequently identified within
the erythroblastic islands, such as α4β1-integrin on erythroblasts and vascular cell adhesion
molecule-1 (VCAM-1) on the central macrophages [39]. Studies from Dr. Chasis’ group
further showed that perturbing the interaction between the erythroid intercellular adhesion
molecule-4 (ICAM-4) and macrophage αV-integrin resulted in the decreased formation of
erythroblastic islands [40]. In addition, several additional surface markers have been
identified on the central macrophage yet their counterpart receptors on erythroid precursors
remain unknown. For example, ER-HR3, a rat monoclonal antibody was found to recognize
a mouse antigen expressed by central macrophages in the mouse [41]. CD169, or
sialoadhesin, was found on central macrophages and binds to an unidentified erythroblast
sialylated glycoprotein within the erythroblastic island [42]. Further, CD163 was also
identified as a macrophage adhesion glycoprotein and functions as a hemoglobinhaptoglobin complex receptor as well as being involved in increasing erythroid expansion
[43].

Author Manuscript

Functionally, one of the most highly specific processes within the erythroblastic island
performed by the central macrophage is the engulfment of the enucleated nucleus [44], and
subsequent recycling of nucleotides after nuclei degradation [45]. Remarkably, the last
division of the developing erythroblast is asynchronous, resulting in the formation of an
enucleated reticulocyte and a pyrenocyte [15]. Both EMP and β1 integrin partition to the
plasma membrane of the pyrenocyte, in order to facilitate its interaction with the central
macrophage and subsequent phagocytosis [46]. Critical to the engulfment of the pyrenocyte
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is the macrophage expression of Mer tyrosine kinase receptor, which recognizes protein S
that is bound to the phosphatidyl serine exposed by the pyrenocyte membrane [16,47].
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While the factors governing the formation of erythroblastic islands remain to be fully
elucidated, candidate genes are emerging. For example, KLF1 directly upregulates the
expression of ICAM4, and KLF1 knockout studies result in significantly reduced levels of
ICAM4 [8,48]. Furthermore, KLF1 has been shown induce the expression of macrophage
DNase2a, a nuclease that leads to the digestion of the pyrenocyte [49]. These findings
illustrate an important role of KLF1 in regulating multiple genes that facilitate erythroid
precursor interactions with the central macrophage in erythroblastic islands. Another
candidate gene identified for the formation of the erythroblastic island is Tropomodulin 3
(Tmod3), an actin-binding protein. Tmod3 is expressed by both erythroblasts and
macrophages, and Tmod3−/− mice present with defective erythroblastic islands [50]. Clearly,
further exploration is needed to identify the specific regulatory networks underlying the
development of erythroblastic islands.
Immunophenotypic characterization of the central macrophage
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A major challenge in the fields of erythropoiesis and macrophage biology has been the
isolation and characterization of the specific functional population of central macrophages,
as the bone marrow houses a widely heterogeneous population of macrophages. To date, it
has not been possible to identify a unique surface protein that is exclusively expressed by the
population of central macrophages. Initial isolation and immunocytochemical
characterization of human central macrophages include CD4, CD11a, CD11c, CD18, CD31,
HLA-DR, FcRI, FcRII, and FcRIII [51]. The F4/80 antigen and Forssman glycosphingolipid
have been described as distinguishing markers of central macrophages but seem to be
restricted to the mouse system [52,53].
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Recent studies have begun to provide new insights into the phenotypic characterization of
populations of macrophages that can be used to analyze the functions of central
macrophages of erythroblastic islands. Using a combination of antibodies specific for
CD169, VCAM-1, ER-HR3, CD11b, F4/80, and Ly-6G, adult mouse bone marrow and
spleen macrophages were isolated via flow cytometry [54]. In the same study, CD169+
specific deletion using a simian diphtheria toxin receptor resulted in the loss of the CD11b+/
F4/80+/VCAM1+/CD169+/ER-HR3+/Ly-6G+ macrophages as well as the loss of
erythroblasts and reticulocytes from the bone marrow and the spleen. The increase in
proerythroblasts, however, suggested a defect in maturation attributable to the disruption of
the erythroblastic island. More interestingly, the same group observed that the
administration of G-CSF to the mouse depleted the above-mentioned population of
macrophages by 90% and reduced medullary erythropoiesis but also observed that G-CSF
increased splenic erythropoiesis and erythroblastic island macrophages [54]. It remains to be
seen how similar or different the populations of macrophages are that reside in the bone
marrow compared to the populations found in the spleen and in the liver. This finding, along
with the knowledge that, in humans, CD169 is expressed by macrophages in the bone
marrow, splenic red-pulp, and liver macrophages [55] implies that CD169 specific depletion
of macrophages is insufficient for the isolation of the bone marrow macrophages involved in
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definitive erythropoiesis. Indeed, in recent studies, splenectomized CD169+ macrophage
depleted mice did not develop overt anemia, and the numbers of splenic red pulp
macrophages and hepatic Kupffer macrophages decreased along with the number of bone
marrow macrophages [56]. The authors reasoned that the number of macrophages involved
in erythrocyte clearance is also decreased and thereby increased the overall life span of the
erythrocytes accounting for the lack of anemia seen in the mice. While the panel of markers
on human bone marrow aspirate may allow for an analysis of a subset of the population of
central macrophages involved, it remains to be seen whether CD15−/CD163+/CD169+/
VCAM1+ is sufficient for isolating a homogenous bone marrow macrophage population
responsible for the formation of the erythroblastic islands in human bone marrow. However,
it is an exciting start to determine if this population expresses the known specific cell
adhesion molecules and which genetic transcription factors define it. Furthermore,
differences in terms of tissue specific extramedullar erythropoietic response to anemia in
mice and man have complicated the design of studies in terms of strategizing experimental
strategies that enable the characterization of the specific functional population of central
macrophages regulating erythropoiesis.

Pathophysiology of anemia of inflammation
At the core of the pathophysiology of anemia of inflammation is the production of the proinflammatory cytokines, IL-1, TNF-α, IFN-γ, and IL-6, which are inhibitory to the
necessary and proper erythropoietic response in the face of anemia [57]. The systemic
pathological processes include decreased EPO production and sensitivity [58], ineffective
erythropoiesis, the dysregulation of iron homeostasis, and the shortened half-life of
erythrocytes due to premature clearance.

Author Manuscript

Insufficient Bone Marrow Response to Erythropoietin
The insufficient bone marrow response to maintain steady-state erythropoiesis during
anemia of inflammation can be partly explained by lower than expected EPO levels when
compared to the levels observed in iron deficiency anemia [59]. In conditions such as
rheumatoid arthritis, anemic patients display low levels of EPO in the plasma [60]. In
addition, the reduced levels of EPO may have a contributing role in the sequestration of iron
in macrophages, as EPO has been shown to negatively affect hepatic production of hepcidin
[61], leading to hypoferremia, as discussed below. However patients with both hematologic
malignancies and anemia of inflammation also have a blunted EPO response [62],
suggesting signaling molecules beyond EPO might be at play.
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In agreement, despite these findings of insufficient EPO production, the low levels of EPO
are not the major mechanism behind anemia of inflammation, as the administration of EPO
is insufficient to correct the anemia in patients [63]. Evidence supporting this theory is
derived from the observation that patients with both renal disease and inflammation with a
serum C-reactive protein (CRP) level of greater than 20 mg/L required higher doses of EPO
than patients with primary EPO deficiency [64]. Furthermore, patients with CRP greater
than 50 mg/L treated with high doses of EPO achieved hemoglobin concentrations less than
that seen in a population of patients with CRP less than 50 mg/L treated with lower doses of
EPO, indicating that the resistance to EPO during inflammation is partly responsible as well
Immunol Res. Author manuscript; available in PMC 2016 December 01.
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[63,65]. Experimentally, studies conducted with the EPO-producing cell line Hep3B,
inflammatory cytokines TNF-α and IL-1 were shown to have an inhibitory effect on EPO
production mainly through the effects of GATA-1 on the EPO promoter, and GATA-1
inhibitors were shown to reverse the suppression of EPO caused by TNF-α and IL-1 [66].
Accordingly, higher levels of EPO are needed to reconstitute the ability for the formation of
CFU-E [67]. Other studies using TNF-α and IL-1 in vitro demonstrated that the effects of
the cytokines are also due to the production of reactive oxygen species that interfere with the
binding affinity of transcription factors that induce EPO expression [68]. An additional
cytokine, IFN-γ has been identified as the major inflammatory cytokine involved in
resistance to EPO response and has been shown to downregulate EPO receptors on erythroid
precursors [69].
Hypoferremia and the role of hepcidin
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The common response to systemic infection and inflammation is the production of IL-6,
which stimulates hepatic production of hepcidin within hours of onset [70] (Figure 3).
Hepcidin is the major regulator of circulating iron plasma levels and acts by binding to the
membrane protein ferroportin, resulting in its internalization and subsequent degradation
[70]. Pathologically excessive levels of hepcidin ultimately lead to a state of hypoferremia
due to the decrease in iron export into the plasma from macrophages and hepatocytes [70].
The degradation of ferroportin also prevents the needed increased ability of duodenal
enterocytes to absorb iron into the circulation [71] (Figure 3). Therefore, induction of
hepcidin by inflammation and subsequent hypoferremia limit erythropoiesis.

Author Manuscript

The antagonist relationship between hepcidin and erythropoiesis was inferred when hepcidin
levels were reduced in mouse models of anemia, following erythroid recovery [72].
Additionally, inhibition of hepcidin required proper production of EPO and a functioning
bone marrow [73]. Recently, erythoferrone (ERFE) was identified as a new negative
regulator of hepcidin. ERFE is produced by bone marrow erythroblasts and acts upon the
liver to suppress hepcidin production [74] (Figure 3). Due to the fact that ERFE is elevated
in β-thalassemia and is involved in the pathology of iron overload [75], perhaps
simultaneous administration of ERFE and iron may be an exciting prospective strategy in
alleviating the entrapment of iron associated with anemia of inflammation.
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While the direct relationship between IL-6 and the induction of hepcidin explains the
inadequate erythropoiesis by limiting iron availability for heme biosynthesis [70], other proinflammatory cytokines can also play a role in iron dysregulation. IFN-γ and TNF-α have
been reported to increase the expression of divalent metal transporter 1 (DMT1) in
macrophages thereby increasing iron uptake [76] (Figure 3). Furthermore, TNF-α, IL-1,
IL-6 and IL-10 all stimulate the sequestration and storage of iron within macrophages by
increasing ferritin expression.
Inflammatory Inhibition of Erythropoiesis
In addition to iron dysregulation, pro-inflammatory cytokines during anemia of
inflammation have been involved in the process of proper proliferation and differentiation of
erythroid precursors. TNF-α, IL-1, and IFN (both –α, -β, and –γ) have been shown to have
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inhibitory effects on the proper development of BFU-E and CFU-E to various extents [67].
Furthermore, IFN-γ has especially prominent negative effects on hemoglobin concentration
and reticulocyte count and also affect the development of early EPO dependent stages of
erythropoiesis, from the CFU-E to the basophilic erythoblast stages [77], by downregulating
EPO receptors as well as decreasing expression of stem-cell factor [69]. Moreover, mouse
studies have shown that IFN-γ can also directly block erythropoiesis by acting even earlier
in developmental stages, at the CMP stage of hematopoiesis, by inducing the expression of
the transcription factor PU.1 [78]. The effects of increased PU.1 expression results in a
lineage switch at the CMP stage, resulting in an increased myeloid differentiation at the
expense of erythroid differentiation, causing decreased numbers of erythroid precursors at
the MEP and BFU-E stages [58]. In human in vitro studies, IFN-γ and other inflammatory
cytokines heightened the sensitivity of EPO dependent erythroid precursors to undergo
extrinsic apoptosis through increased expression of TNF superfamily receptors [79,80].
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The other major inflammatory cytokine, TNF-α, can lead to erythrocyte damage induced by
free radicals, resulting in an increase in erythrophagocytosis [81]. The interaction between
TNF-α and erythroid precursors was further examined in the context of rheumatoid arthritis,
in which up to 50% of patients exhibit anemia of chronic disease [82]. Increased TNF-α
levels have been shown in vitro to inhibit the production of erythroid colony formation
[83,84], and increased serum levels of TNF-α have been positively correlated with
increasing degrees of anemia associated with rheumatoid arthritis [85]. Additionally, human
bone marrow samples from these patients have decreased numbers of erythroid progenitor
and precursor cells, low BFU-E colony formation, due to increased apoptosis in the
erythroid precursor populations [86]. Further evidence in the same study supported the role
of TNF-α in anemia of inflammation as the administration of anti-TNF-α antibody not only
increased hemoglobin concentration, but also reduced the proportion of apoptotic cells in
both the erythroid progenitor and precursor populations [86].

Erythroblastic Islands in Anemia of Inflammation
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As mentioned earlier, the administration of recombinant erythropoietin remains as a useful
but incomplete means of stimulating erythropoiesis in anemia of inflammation. Indeed, EPO
administration increases hemoglobin concentration (and hematocrit) but does not reduce the
number of red cell transfusions needed to correct the anemia [87]. Because recent studies
have suggested a role for erythroblastic islands during stress erythropoiesis [56] and their
involvement in supporting altered proliferation of erythroid precursor cells in a disease
context such as polycythemia vera [88], increasing attention in the field is now focused on
structural and molecular protein interactions between developing erythroblasts and central
macrophages as well as the transcription factors that regulate these processes in the central
macrophage. Our review not only recognizes these questions as crucial in understanding
definitive erythropoiesis, but also extends the question to the role of these bone marrow
central macrophages in the context of anemia of inflammation, particularly concerning the
set of chemokines and cytokines that are produced both systemically and by the
macrophages themselves that may have an effect on erythropoiesis per se.
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Central to our question on macrophage function in the context of anemia of inflammation
are the cytokines that are produced by these central macrophages within the erythroblastic
island and their subsequent effects on erythropoiesis. Cellular interactions within the
erythroblastic islands are complicated by a series of paracrine and autocrine signaling
pathways. For example, Gas6 enhances Epo receptor signaling on erythroblasts and binds to
its receptor on macrophages to reduce erythroid inhibitory factors [89]. Factors secreted by
macrophages can also positively influence erythropoiesis such as insulin-like growth
factor-1, which stimulates erythropoiesis at both the BFU-E and CFU-E stages [90]. While
these positively regulating cytokines are important for the proper balance of erythropoiesis,
much attention has also been diverted to the negatively regulating cytokines, especially
those produced by underlying conditions such as autoimmune disorders or chronic infections
that cause a systemic state of inflammation. However, as previously mentioned, local
increased levels of TNF-α, IL-6, IFN-γ, and TGF-β in the bone marrow have also been
associated with anemia of chronic inflammation [91]. TNF-α suppresses erythropoiesis
through the caspase-activated cleavage of GATA-1, without which erythroid development is
impaired and results in apoptosis [92] or in the disruption in proliferation of erythroid
progenitors [93]. In addition, TNF-α has an effect on macrophages, causing a release of
metalloproteases to disturb the adhesive interactions necessary for erythroblast island
formation [94]. TGF-β activates Rho and Rac GTPases, altering the actin cytoskeleton that
is finely tuned by cytoskeletal proteins within the erythroblasts, compromising the integrity
of the cell membrane [95]. IFN-γ causes the secretion of TNF-related apoptosis inducing
ligand (TRAIL) by both macrophages and erythroblasts, which activates ERK/MAPK to
inhibit erythroblast differentiation [96,97] (Figure 2).
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In addition to their identity, a related question is whether anemia of inflammation alters
polarization of the central macrophage in the erythroblastic island and whether this process
interferes with erythroblast development. Classically, activation of macrophages to the
polarized M1 state is due to the production of reactive oxygen species and pro-inflammatory
cytokines [98]. Conversely, the M2 polarization of macrophages is activated by IL-4, IL-13,
TGF-β, and glucocorticoids and involves the regulation of the resolution phase of
inflammation [99]. Upon comparison of gene expression profiles of genes related to iron
homeostasis, over 60% of those genes were differentially expressed between M1 and M2
macrophages [100]. Whereas the M1 macrophages were shown to induce gene expression
patterns that allow for iron sequestering, M2 macrophages not only downregulated
expression of ferritin, but also actively exported iron through ferroportin [101]. One
particularly interesting difference was the increased expression of CD163 by M2
macrophages, allowing for an increased ability to bind and internalize hemoglobin/
haptoglobin complexes, a process necessary for the detoxification of heme associated iron
[102]. Interestingly, CD163 was used as one of the cell surface markers used to isolate
populations of bone marrow macrophages associated with erythroblastic islands that
expressed both VCAM1 and CD169 [56]. It also seems that CD163 can act to mediate the
binding of macrophages to erythroid precursors to induce proliferation and continued
differentiation [43]. This suggests that the macrophage population supporting erythroblastic
island formation exhibit gene expression profiles closer to the M2 polarization, but the
degree of this overlap is still uncertain.
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While the M1 and M2 classifications broadly describe the population that may include those
of the central macrophages, a functional characterization guided by gene expression profiles
is needed to validate and study a homogenous population of macrophages specific for the
formation of erythroblastic islands. While our knowledge of the necessary transcription
factors for these macrophages is incomplete, it is known that the retinoblastoma tumor (Rb)
protein is crucial for the proper differentiation of these macrophages [103]. In Rb−/− mice,
fetuses are severely anemic and die in utero from abnormal fetal liver erythropoiesis and
failure of enucleation [104]. In addition to the role of Rb in erythroblasts [105,106],
experimental evidence suggests a role of Rb in macrophages as well, since macrophages do
not properly differentiate due to the inability of Rb to stop the inhibition of PU.1 by inhibitor
of DNA-binding protein 2 (Id2) in Rb−/− mice [103]. Another example is the transcription
factor c-Maf, which recognizes Maf recognition elements (MARE) or 5′ AT-rich half
MARE in order to bind to DNA and regulate cellular proliferation and differentiation
[107,108]. c-Maf was found to be expressed highly in fetal liver macrophages and necessary
for the development of erythroblastic islands [109]. Further, it was found that the reduction
of c-Maf resulted in decreased expression of VCAM-1, contributing to the defective
interactions necessary for erythroblastic island development [109]. Other transcription
factors that regulate specific cellular proteins and processes to the central macrophages
remain unknown, particularly those that control the expression of EMP, αV-integrin, and the
cytoskeletal-associated proteins that enable proper island formation and erythroblast
enucleation.
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Recently, the findings of KLF1 expression in macrophages has raised questions of not only
the transcriptional machinery that regulates central macrophage function, but also on the
ontogeny of the macrophages that comprise the erythroblastic islands [54,110]. The current
dogma describes macrophages deriving from granulocyte-monocyte progenitors and
erythroid cells from the MEP, with each progenitor population arising from the more
developmentally immature population, the common myeloid progenitor, or CMP. In
addition to this concept it is widely accepted that KLF1 is a transcription factor that is highly
specific to the erythroid cell lineage [8]. A recent study challenges both these concepts by
documenting that mouse embryonic stem cells could generate a clonal line giving rise to
both erythroid cells and macrophages, which together formed physical structures that
resembled that of erythroblastic islands [111]. It is still unknown, however, the correlation
of these macrophages, anatomically and temporally to the erythroblastic islands, whether
primitive, fetal, or bone marrow definitive [54].
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Macrophages also play an important role in iron homeostasis. As mentioned earlier,
hepcidin and the sequestration of iron in bone marrow macrophages play a pivotal role in
contributing to the development of anemia of chronic inflammation. The recycling of iron
begins as senescent and damaged erythrocytes are detected and engulfed by splenic red pulp
macrophages [112]. Mechanisms in place for the surveillance of aging red cells are
associated with the continual remodeling of the membrane as the erythrocytes circulate and
are exposed to both oxidative and mechanical stress [113]. Other studies have described
mechanistic details for the removal of aged erythrocytes, including those that describe the
roles of band 3, phosphatidylserine, CD47, and complement receptor 1 [114–117]. After the
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ingestion of erythrocytes by macrophages into phagolysosomes, hemoglobin is degraded
into heme and iron for recycling processes aided by heme-responsive gene 1 protein [118],
and the cytosolic iron cations are further processed for transport by natural resistance
associated macrophage protein (Nramp1) and divalent metal transporter 1 (DMT1) [119].
While the majority of the recycled iron supply is redistributed by transferrin molecules to
return to developing erythroblasts to aid in the production of hemoglobin, some evidence
suggests that macrophages may have a role in directly supplying iron to erythroid
precursors, originally suggested by Marcel Bessis [120]. In co-culture experiments with
human peripheral macrophages and erythroblasts grown in transferrin-free conditions,
ferritin expression and evidence of exocytosis by the macrophages was documented [121].
However, the mechanisms by which macrophages, especially those that reside in the bone
marrow, directly transfer iron into developing erythroblasts are still unknown. Therefore, a
better understanding of iron metabolism in the erythroblastic island would certainly further
our knowledge of the pathologic cellular events in the context of anemia of inflammation.

Of mice, rats and men: which model to study anemia of inflammation
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Throughout the development of the hematopoietic system in vertebrates, the pool of
progenitor populations giving rise to red cells occur not only in multiple temporal waves but
at various anatomic sites throughout the body as well [122]. Similarly, it is likely that
erythroblastic island macrophages and their progenitors reflect anatomical and
developmental-specific populations. The laboratory mouse (Mus musculus) is a widely used
model system in biology, and has been critical for the discovery of hematopoietic genes and
our understanding of the ontogeny of the two distinct erythroid lineages, embryonically
primitive and the adult definitive [123–125]. While these studies have provided a wealth of
knowledge in understanding normal physiology of the human erythropoiesis, the differences
between the species has complicated the direct relevance of the findings from the murine
system to humans in the context of anemic disease and stress erythropoiesis, particularly
concerning the role of the population of central macrophages. Therefore, by outlining the
similarities and differences among mice, humans and rats we offer considerations for in vivo
experiments aimed at understanding erythroblastic island physiology and pathology, and
suggest that the rat is a better system for the study of erythroblastic islands.
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Three developmental waves characterize the establishment of mammalian hematopoietic
systems [126]. The first wave of hematopoiesis occurs at the site of the yolk sac, and
together with macrophages and megakaryocytes, primitive erythrocytes (EryP) [127] are
produced from hemangioblasts [128]. During the initial embryonic primitive phase of
erythropoiesis, the EryP cells are characterized as large, nucleated cells and persist only for
a transiently short period up until birth [129–132]. EryP cells retain their nucleus for the
initial phase of their circulation during gestation until they also ultimately expel their nuclei
as they mature within the circulation [132]. A subsequent transient wave from the yolk sac is
then termed as the second wave, consisting of definitive erythroid cells (EryD),
megakaryocyte, and myeloid lineage cells [129]. In contrast to EryP, these erythrocytes
originate from BFU-Es that migrate to the fetal liver from the yolk sac and develop
extravascularly to enucleate before entering the circulation [131]. The third and final wave
arises from HSCs originating from the major embryonic arteries, which seed the fetal liver;
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later these definitive HSCs colonize the bone marrow [127,133,134]. In addition to their
anatomic differences, it is currently proposed that definitive erythroid populations arise from
discrete progenitors. Indeed, the first definitive erythroid population arises from the yolk sac
erythroid myeloid progenitor population and the second wave of definitive erythroid
population is seeded by the hematopoietic stem cell population arising from the major
embryonic arteries [135]. Both phases of definitive erythropoiesis are characterized by
extravascularly enucleated red cells and correlate with the formation of the erythroblastic
island which have been observed in the fetal liver, bone marrow, and the red pulp of the
spleen in the murine system [136]. Since these blood cells derive from separate progenitors,
we may infer that the central island macrophage could originate from two distinct
populations.
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In contrast to developmental embryonic erythropoiesis, humans, mice, and rats possess
divergent steady-state erythropoiesis in the adult. Unlike the human hematopoietic system,
where erythropoiesis predominates in the bone marrow, the mouse spleen continually houses
hematopoietic stem cells and remains a major organ contributing to erythropoiesis in
response to anemia [137]. While bone marrow erythropoiesis in humans can generate 20fold more red cells upon stimulation than at steady state, murine bone marrow erythropoiesis
can increase red cell production less that 2-fold. Furthermore in rats, the shift of
erythropoiesis from the spleen to the bone marrow is much more significant [138], with the
adult rat spleen contributing less than 5% of its total erythropoietic activity and all of
increased red cell production taking place in the bone marrow in response to anemia [139].
This is a much smaller fraction of splenic contribution of erythropoiesis than that occurs in
the mouse [140]. Thus, erythropoiesis in the rat is highly reminiscent of human
erythropoieisis.
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An even greater difference among murine, rat, and human erythropoiesis is observed under
anemic and/or hypoxic conditions, which activates a stress response to increase
erythropoiesis, rapidly increasing the generation of replacing erythrocytes [141–143]. In
mice, the spleen is the primary site for stress erythropoiesis [142,144–149], with the liver
also involved as an extramedullary site for erythropoiesis [150,151]. It has also been well
documented that spleen-derived stress erythroid progenitor cells of mice are distinct from
the erythroid progenitor cells that are active during steady state erythropoiesis in the bone
marrow [142]. Mechanistic insight from these studies detailed a distinct resident population
of erythroid progenitors in the spleen of mice that utilize a BMP4-dependent stress
erythropoiesis pathway and more importantly, the authors highlighted that such a pathway
for human extramedullary stress erythropoiesis has not been identified. In fact, unless under
pathologic conditions, splenic erythropoiesis is not a feature of stress erythropoiesis in
humans except in case of myelofibrosis and other conditions in which the bone marrow
space is exhausted for red cell production. Furthermore, the contribution of splenic
erythropoiesis when recovering from anemic conditions was found to be minimal in rats
[152]. Together, we conjecture that the populations of macrophages that provide a
microenvironment for erythropoiesis correlate and differ accordingly based on anatomic
location and because of this, likely influence the necessary capabilities of extramedullary
stress erythropoiesis. Central to our understanding of the role of erythroblastic islands during
pathologic conditions is the ability to study homologous systems. As rat and human adult
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definitive erythropoiesis share more commonalities than human and murine erythropoiesis,
we propose that the rat hematopoietic system represents a more faithful in vivo model to
study the role of erythroblastic islands in the context of anemia of inflammation.

Conclusions
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A fuller understanding of the positive and negative regulators of central macrophage of the
erythroblastic islands is vital for developing novel therapeutic strategies. As various
pathologic inflammatory conditions disrupt the erythropoietic response via inflammatory
cytokines, it is conceivable that these deleterious effects could be mitigated by the
appropriate administration of antibodies that target purified populations of central
macrophages must be reproducibly identified and isolated in a manner that allows for them
to be studied using global approaches such as RNAseq and comprehensive proteomic
analyses. Secondly, it is important to determine how each inflammatory cytokine, both
independently and in concert with other cytokines, disrupts the integrity of the erythroblastic
island. For example, what process of erythroblast enucleation is most compromised? What
stage of erythroblast development is most vulnerable to the disruption of the erythroblastic
island? Is the pathologic process an issue with the ratio of central macrophages to
erythroblast precursors or an issue with the absolute number of central macrophages
available in the bone marrow? Furthermore, a more complete understanding of
erythroblastic islands will not only benefit our understanding of red blood cell pathologies,
but also, the ability to differentiate sufficient numbers of red blood cells in vitro for
transfusions using a universal donor derived progenitor cell at either the hematopoietic stem
cell or pluripotent stem cell stage [153,154].
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To our knowledge, there has yet to be a universal ex vivo system capable of producing
sufficient numbers of fully mature and functional erythrocytes on an economic mass scale
for the use of widespread clinical transfusions [155]. Perhaps a complete understanding of
the interplay between central macrophages and erythroblasts may unravel novel strategies to
provide such a method.
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Figure 1. Erythropoiesis and its modulation by hormones and inflammatory cytokines
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Erythropoiesis begins with the hematopoietic stem cell which gives rise to the common
myeloid progenitor (CMP), the megakaryocyte erythrocyte progenitor (MEP) and the Burst
Forming Unit (BFU-E), which all develop sequentially within the microenvironment of the
bone marrow. Starting at the Colony Forming Unit (CFU-E) stage, cells begin to attach and
interact with the central macrophage to form the erythroblastic island and begin hemoglobin
synthesis starting at the basophilic erythroblast stage until the formation of the reticulocyte,
which then enters the circulation. Inflammatory cytokines interrupt the process of
erythropoiesis at several stages of development. IFN-γ interferes at the CMP stage to push
towards the megakaryocyte lineage, decreasing the numbers of MEP and BFU-E. IFN-γ also
increases the number of Fas receptors leading to apoptosis of the EPO-R expressing stages
of erythoid precursor cells. TNF-α and IL-1 together interact through GATA-1 to decrease
the production of EPO. During stages of hemoglobin synthesis, the production of IL-6 and
hepcidin prevent the availability of iron to the erythroblasts.
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Figure 2. The erythroblastic island
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From the CFU-E stage to the formation of the reticulocyte, developing erythroblasts attach
to a central macrophage located in the bone marrow through the use of α4β1, EMP, and
ICAM4. The central macrophage mediates these interactions through VCAM1, EMP, αvβ3
respectively. Other cell surface identifiers expressed by the macrophage are CD163, CD169,
F4/80, and ER-HR3. The inflammatory cytokines produced by the macrophages within the
context of anemia of inflammation are known to inhibit erythropoiesis, particularly IFN-γ,
TNF-α, TRAIL, and IL-6.
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Figure 3. Hepcidin in anemia of inflammation
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The state of inflammation initiated by underlying causes such as overwhelming and/or
chronic infection, autoimmune diseases, or malignancies lead to the production of IL-6
which act on the liver to produce hepcidin, ultimately decreasing ferroportin at both the
enterocytes located at the duodenum and splenic macrophages. The increased iron retention
by macrophages and decreased iron absorption by the enterocytes lead to a state of
hypoferremia. Recently, an erythroid regulator called erythroferrone has been shown to
inhibit the production of hepcidin. Iron retention by the macrophage is further regulated by
IFN-γ.
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Figure 4. Anatomic sites of erythropoiesis in mammals during development and pathological
conditions
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A. During the course of embryonic development in human and mice, the yolk sac is the first
source of erythrocytes to provide the fetus with oxygen. Throughout development, fetal liver
contributes as the main source of erythropoiesis with the yolk sac regressing. At the time of
birth, the bone marrow emerges as the main source of erythropoiesis with the seeding of the
hematopoietic stem cells. However, a notable difference is the contribution to erythropoiesis
of the spleen in the mouse till 3 months of age. In humans, the sites of erythropoiesis change
over time as red blood cell production recedes in the long bones (tibia, femur) and persists in
the flat bones (sternum, skull, ribs, pelvis). B. During stress erythropoiesis, the sites of
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erythropoiesis in the adult human are primarily the flat bones of the skull, sternum, and
pelvis with minor contributions from the liver and less so from the spleen. Contributions
from the liver and the spleen do not normally occur unless under pathologic disease states.
In the mouse system, splenic erythropoiesis is a main feature of stress erythropoiesis with
erythroid progenitors in the spleen having being well studied and described. Conversely in
the rat, the spleen is a minor contributor of erythropoiesis during times of stress.
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